Moderna CEO Warns of China's Heavy Investment in mRNA Technology Amid US Funding Pullback
Moderna CEO Stéphane Bancel has issued a warning regarding China's substantial state-backed investments in mRNA biotechnology, contrasting it with a reduction in U.S. funding for similar projects. Bancel highlighted that while the U.S. Department of Health and Human Services (HHS) has scaled back nearly $500 million in mRNA vaccine development projects through the Biomedical Advanced Research and Development Authority (BARDA), China is actively pouring state money into this sector. The Chinese Communist Party has designated biotechnology as a 'strategic emerging industry,' providing significant financing and subsidies to domestic firms with the aim of dominating key areas of the industry. Bancel emphasized the importance of maintaining drug manufacturing within the U.S., citing Moderna's facilities in Massachusetts, to safeguard both American patients and the nation's leadership in healthcare. He noted that the mRNA technology has demonstrated its efficacy during the COVID-19 pandemic with vaccines and is ... 
